• Price (USD)4.15
  • Today's Change0.08 / 1.97%
  • Shares traded11.95k
  • 1 Year change+15.28%
  • Beta1.2144
Data delayed at least 15 minutes, as of Jun 01 2023 20:59 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Genfit SA is a France-based biopharmaceutical company that specializes in the development of medicines for the prevention and treatment of diabetes and related disorders. The Company is focused on contributing to bringing medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver, such as Nonalcoholic steatohepatitis (NASH) or the bowel, such as the inflammatory bowel disease. The Company targets a number of therapeutic areas, which includes nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), NASH diagnosis, NASH-induced fibrosis and IL-17 dependent autoimmune diseases. The Company’s research programs develop diversified pipeline of drug candidates, including Elafibranor in NASH, which is in phase III; Elafibranor in PBC, which is in phase II; In-Vitro diagnostic test for NASH and Nitazoxanide in fibrosis, which is still in clinical stage, among others.

  • Revenue in USD (TTM)28.59m
  • Net income in USD-25.52m
  • Incorporated1999
  • Employees148.00
  • Location
    Genfit SAParc Eurasante 885 avenue Eugene AvineeLOOS 59120FranceFRA
  • Phone+33 320164000
  • Fax+33 320164001
  • Websitehttps://www.genfit.fr/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
GNFT:PAR since
Versantis AGDeal completed19 Sep 202219 Sep 2022Deal completed-4.33%108.85m
Data delayed at least 15 minutes, as of Jun 02 2023 12:03 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
ADC Therapeutics SA182.40m-198.57m191.93m317.00--5.09--1.05-2.52-2.522.300.46730.34760.14237.18575,400.60-37.84-47.88-44.24-54.3498.83---108.86-352.484.46-5.590.9001--518.89158.9432.27---6.15--
AC Immune SA4.35m-76.68m192.33m126.00--1.14--44.25-0.9152-0.91520.05192.020.0195--21.2734,497.03-34.31-18.28-36.35-19.56-----1,764.17-154.12----0.0171-----27.943.06---7.22--
Aadi Bioscience Inc18.78m-61.88m193.05m80.00--1.32--10.28-2.64-2.640.78245.970.120.84154.54237,670.90-39.54-50.93-43.62-56.0191.03---329.56-405.079.08--0.00--1,258.57--45.03--118.57--
Ocean Biomedical Inc0.00-958.42k194.55m9.00--0.7253-----0.0725-0.07250.007.890.00----0.00-0.873---0.888--------------0.0202-------69.90------
XOMA Corp3.36m-30.11m194.95m12.00--1.70--58.07-2.63-2.630.29339.990.0229--216.58279,750.00-16.83-0.6127-17.93-0.6706-----733.90-3.43----0.00---84.21-35.19-383.33--352.92--
Zomedica Corp20.66m-19.46m195.01m85.00--0.7413--9.44-0.0199-0.01990.02110.26840.07411.8717.78243,070.60-6.98-17.78-7.14-18.3371.27---94.20-384.7814.82--0.006--358.01--7.44--74.64--
Citius Pharmaceuticals Inc0.00-30.97m196.98m21.00--1.99-----0.2119-0.21190.000.62320.00----0.00-26.70-31.66-28.08-33.78------------0.00-------37.28------
Poseida Therapeutics Inc139.40m-44.79m197.85m343.00--1.26--1.42-0.6054-0.60541.791.820.4963----443,949.00-15.95-44.02-19.09-50.94-----32.13-278.04---5.810.2702--317.73112.8848.79--81.18--
Kinnate Biopharma Inc0.00-122.31m200.26m94.00--0.8989-----2.75-2.750.004.780.00----0.00-41.29---46.53--------------0.00-------29.53------
Genfit SA (ADR)28.59m-25.52m200.27m148.00--2.03--7.01-0.5138-0.51380.57552.040.1069531.0016.38193,160.30-9.54---12.01--92.00---89.29--4.02--0.4433---68.96---135.27------
Kezar Life Sciences Inc0.00-74.41m201.29m84.00--0.7797-----1.06-
Gracell Biotechnologies Inc (ADR)0.00-85.64m201.79m314.00--1.04-----1.27-
Akebia Therapeutics Inc271.03m-56.36m202.66m204.00------0.7478-0.3112-0.31121.46-0.07720.66741.336.581,328,578.00-13.88-35.87-23.71-52.6585.2669.23-20.79-87.941.21-2.421.40--37.0010.0667.27---41.20--
Eyepoint Pharmaceuticals Inc39.79m-102.44m204.44m144.00--2.61--5.14-2.74-2.741.062.290.19941.942.65276,340.30-51.33---60.27--81.93---257.44--5.21--0.3066--12.09---75.04------
Altimmune Inc-79.00k-85.36m204.56m52.00--1.22-----1.76-1.76-0.00163.40-0.0004-----1,519.23-43.47-41.05-47.60-44.12-------1,013.75----0.00---101.54--12.75---5.40--
Acumen Pharmaceuticals Inc0.00-45.03m205.13m39.00--1.15-----1.11-
Data as of Jun 01 2023. Currency figures normalised to Genfit SA's reporting currency: US Dollar USD

Institutional shareholders

4.34%Per cent of shares held by top holders
HolderShares% Held
Tang Capital Management LLCas of 20 Apr 20231.21m2.44%
Adage Capital Management LPas of 31 Mar 2023516.06k1.04%
DAFNA Capital Management LLCas of 31 Mar 2023197.94k0.40%
Millennium Management LLCas of 31 Mar 202357.78k0.12%
Morgan Stanley & Co. International Plcas of 31 Mar 202343.23k0.09%
Ikarian Capital LLCas of 31 Mar 202332.79k0.07%
Optiver US LLCas of 31 Mar 202326.84k0.05%
Envestnet Asset Management, Inc.as of 31 Dec 202226.55k0.05%
O'Shaughnessy Asset Management LLCas of 31 Mar 202324.46k0.05%
Two Sigma Investments LPas of 31 Mar 202321.37k0.04%
More ▼
Data from 31 Mar 2023 - 31 Mar 2023Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.